Nuclear and Glial Dysfunction in Neurodegeneration
神经退行性变中的核和神经胶质功能障碍
基本信息
- 批准号:10664230
- 负责人:
- 金额:$ 122.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-16 至 2031-04-30
- 项目状态:未结题
- 来源:
- 关键词:ALS patientsAgingAstrocytesBiological ModelsBiologyC9ALSC9ORF72Cell LineCellular biologyDataDefectDegenerative DisorderDementiaDendritesDevelopmentDiseaseDisease MarkerDrosophila genusEducational process of instructingElementsFunctional disorderFutureHealthHumanHuntington DiseaseInduced pluripotent stem cell derived neuronsInjuryLearningLinkLocationModelingMotor NeuronsMutationNerve DegenerationNervous System TraumaNeurodegenerative DisordersNeurogliaNeuronsNuclearNuclear PoreNuclear Pore ComplexPathogenicityPathologyPathway interactionsPatientsProcessPropertyProteinsRodentSubgroupSynapsesSystemTherapeuticValidationVertebral columnbrain tissuecandidate identificationcell typedrug actiondrug discoveryflyfrontotemporal lobar dementia amyotrophic lateral sclerosishuman diseasein vivoinduced pluripotent stem cellinsightloss of functionmolecular subtypesmouse modelmutantnovel therapeuticsnucleocytoplasmic transportprotein TDP-43repairedsporadic amyotrophic lateral sclerosistherapeutic candidatetool
项目摘要
Abstract
In the last 5–10-years new model systems, to study ALS, FTD and other dementias, based on patient derived
induced pluripotent cell lines have provide great insight into highly relevant disease-causing pathways as well
as fundamental neuronal and glial cell biology. New studies using these, and other model systems suggest
the nuclear transport is the fundamental injury linked to both familial sporadic ALS and FTD. Emerging
studies now implicate nuclear transport and the nuclear pore complex in multiple different neurodegenerative
diseases including ALS, FTD, Huntington’s disease and even aging. These studies are beginning to identify
candidate therapies for sporadic forms of the disease. The nuclear pore complex is diverse, and mutations of
its constituent proteins can lead to a wide range of different degenerative diseases. Thus, studies of the CNS
nuclear pore and nucleocytoplasmic transport have pathogenic implications that are wide ranging. This
proposal will comprehensively investigate the biology of CNS nuclear pores and nuclear transport- the
fundamental properties in different neuronal and glia, mechanisms by which the nuclear pore is disrupted,
include possibly disease initiating biology involving the ESCT3/CHMP7 pathways, how the nuclear pore
complex is disrupted in sporadic and familial forms of the diseases utilizing several complementary models
including C9-ALS fly and mouse models and iPS neurons and brain tissue from sporadic and C9orf72 mutant
ALS/FTD patients. We will also investigate whether modulation of nucleocytoplasmic transport and /or repair
of the nuclear pore complex may be a therapeutic strategy for ALS/FTD. Our emerging data teach that there
are multiple candidate therapeutic opportunities for this pathway and neurodegeneration. As we have now
learned that defect on the nuclear pore complex are upstream of the disruption of TDP43 nuclear location and
loss of function, this pathway may have relevance to not only ALS and FTD – but other neurological injuries
involving TDP43 misregulation. Finally, studies over the last decade have revealed that neurodegenerative
diseases are not simply a disorder of neurons, but that glial cells also contribute to pathophysiology. Many
studies have implicated aberrant astroglial function in ALS and neurodegeneration. Regional alterations of
astroglia have long been known—but how this occurs and whether astroglia exist as functional/molecular
subtypes has been unclear. New studies from our group and others now suggests real subtypes of astroglia
exist, may have specific functions n modulating cortical dendritic and synaptic biology and may be selectively
altered in ALS. The biology of these newly identified subgroups will be explored in this proposal and how they
alter spines/dendrites, neuronal elements known to be dramatically altered in neurodegeneration.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey D Rothstein其他文献
Mechanisms of Disease: astrocytes in neurodegenerative disease
疾病机制:神经退行性疾病中的星形胶质细胞
- DOI:
10.1038/ncpneuro0355 - 发表时间:
2006-12-01 - 期刊:
- 影响因子:33.100
- 作者:
Nicholas J Maragakis;Jeffrey D Rothstein - 通讯作者:
Jeffrey D Rothstein
Advances in neuromuscular disorders 2024
《2024 年神经肌肉疾病研究进展》
- DOI:
10.1016/s1474-4422(24)00489-7 - 发表时间:
2025-01-01 - 期刊:
- 影响因子:45.500
- 作者:
Jeffrey D Rothstein;Ahmet Hoke;Payam Mohassel - 通讯作者:
Payam Mohassel
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with emC9orf72/em-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study
反义寡核苷酸 BIIB078 在患有 emC9orf72/em 相关肌萎缩侧索硬化症的成年人中的安全性、耐受性和药代动力学:一项 1 期、随机、双盲、安慰剂对照、多次递增剂量研究
- DOI:
10.1016/s1474-4422(24)00216-3 - 发表时间:
2024-09-01 - 期刊:
- 影响因子:45.500
- 作者:
Leonard H van den Berg;Jeffrey D Rothstein;Pamela J Shaw;Suma Babu;Michael Benatar;Robert C Bucelli;Angela Genge;Jonathan D Glass;Orla Hardiman;Vincenzo Libri;Theodore Mobach;Björn Oskarsson;Gary L Pattee;John Ravits;Christopher E Shaw;Markus Weber;Lorne Zinman;Paymaan Jafar-nejad;Frank Rigo;Luan Lin;Stephanie Fradette - 通讯作者:
Stephanie Fradette
Investigating the Protective Role of the Mitochondrial 2158 T > C Variant in Parkinson's Disease.
研究线粒体 2158 T > C 变体在帕金森病中的保护作用。
- DOI:
10.1002/mds.29892 - 发表时间:
2024 - 期刊:
- 影响因子:8.6
- 作者:
F. Akçimen;Vesna van Midden;S. C. Akerman;Mary B Makarious;Jeffrey D Rothstein;Zih;Sara Bandres - 通讯作者:
Sara Bandres
Jeffrey D Rothstein的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey D Rothstein', 18)}}的其他基金
Astrocyte Norrin, Norrie disease and Neurodegeneration
星形胶质细胞诺里蛋白、诺里病和神经变性
- 批准号:
10383676 - 财政年份:2019
- 资助金额:
$ 122.81万 - 项目类别:
ALS/FTD mutant C9orf72-induced genetic and nuclear pathology in iPS cell models
ALS/FTD 突变体 C9orf72 在 iPS 细胞模型中诱导遗传和核病理学
- 批准号:
8613778 - 财政年份:2013
- 资助金额:
$ 122.81万 - 项目类别:
ALS/FTD mutant C9orf72-induced genetic and nuclear pathology in iPS cell models
ALS/FTD 突变体 C9orf72 在 iPS 细胞模型中诱导遗传和核病理学
- 批准号:
8913279 - 财政年份:2013
- 资助金额:
$ 122.81万 - 项目类别:
ALS/FTD mutant C9orf72-induced genetic and nuclear pathology in iPS cell models
ALS/FTD 突变体 C9orf72 在 iPS 细胞模型中诱导遗传和核病理学
- 批准号:
8724576 - 财政年份:2013
- 资助金额:
$ 122.81万 - 项目类别:
ALS/FTD mutant C9orf72-induced genetic and nuclear pathology in iPS cell models
ALS/FTD 突变体 C9orf72 在 iPS 细胞模型中诱导遗传和核病理学
- 批准号:
9314638 - 财政年份:2013
- 资助金额:
$ 122.81万 - 项目类别:
ALS/FTD mutant C9orf72-induced genetic and nuclear pathology in iPS cell models
ALS/FTD 突变体 C9orf72 在 iPS 细胞模型中诱导遗传和核病理学
- 批准号:
8989628 - 财政年份:2013
- 资助金额:
$ 122.81万 - 项目类别:
ALS/FTD mutant C9orf72-induced genetic and nuclear pathology in iPS cell models
ALS/FTD 突变体 C9orf72 在 iPS 细胞模型中诱导遗传和核病理学
- 批准号:
9119869 - 财政年份:2013
- 资助金额:
$ 122.81万 - 项目类别:
Therapeutic Expression of Glial Glutamate Transporters
神经胶质谷氨酸转运蛋白的治疗性表达
- 批准号:
7475723 - 财政年份:2005
- 资助金额:
$ 122.81万 - 项目类别:
相似海外基金
Long Non-coding RNA Regulation in Astrocytes within the Aging Brain
衰老大脑中星形胶质细胞的长非编码RNA调控
- 批准号:
10195946 - 财政年份:2021
- 资助金额:
$ 122.81万 - 项目类别:
Long Non-coding RNA Regulation in Astrocytes within the Aging Brain
衰老大脑中星形胶质细胞的长非编码RNA调控
- 批准号:
10392421 - 财政年份:2021
- 资助金额:
$ 122.81万 - 项目类别:
Long Non-coding RNA Regulation in Astrocytes within the Aging Brain
衰老大脑中星形胶质细胞的长非编码RNA调控
- 批准号:
10602434 - 财政年份:2021
- 资助金额:
$ 122.81万 - 项目类别:
Function of reactive astrocytes in aging and neurodegenerative disease
反应性星形胶质细胞在衰老和神经退行性疾病中的功能
- 批准号:
10045701 - 财政年份:2020
- 资助金额:
$ 122.81万 - 项目类别:
Function of reactive astrocytes in aging and neurodegenerative disease
反应性星形胶质细胞在衰老和神经退行性疾病中的功能
- 批准号:
10476015 - 财政年份:2020
- 资助金额:
$ 122.81万 - 项目类别:
Function of reactive astrocytes in aging and neurodegenerative disease
反应性星形胶质细胞在衰老和神经退行性疾病中的功能
- 批准号:
10689121 - 财政年份:2020
- 资助金额:
$ 122.81万 - 项目类别:
Function of reactive astrocytes in aging and neurodegenerative disease
反应性星形胶质细胞在衰老和神经退行性疾病中的功能
- 批准号:
10480931 - 财政年份:2020
- 资助金额:
$ 122.81万 - 项目类别:














{{item.name}}会员




